La hidroxicloroquina como fármaco fundamental en dermatología y su papel controvertido en la COVID-19

Fernandez, 2017, Updated recommendations on the use of hydroxychloroquine in dermatologic practice, J Am Acad Dermatol., 76, 1176, 10.1016/j.jaad.2017.01.012 Chew, 2020, Hydroxychloroquine in dermatology: New perspectives on an old drug, Australas J Dermatol., 61, e150, 10.1111/ajd.13168 Sardana, 2020, Hydroxychloroquine in dermatology and beyond: Recent update, Indian Dermatol Online J., 11, 453, 10.4103/idoj.IDOJ_280_20 Cox, 2020, To dispense or not to dispense: Lessons to be learnt from ethical challenges faced by pharmacists in the COVID-19 pandemic, Dev World Bioeth. Baral, 2021, Competing health risks associated with the COVID-19 pandemic and response: A scoping review, medRxiv. Melles, 2014, The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy, JAMA Ophthalmol., 132, 1453, 10.1001/jamaophthalmol.2014.3459 Mohammad, 2018, Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-deficient patients, Arthritis Care Res (Hoboken)., 70, 481, 10.1002/acr.23296 Peschken, 2020, Possible consequences of a shortage of hydroxychloroquine for patients with systemic lupus erythematosus amid the COVID-19 pandemic, J Rheumatol., 47, 787, 10.3899/jrheum.200395 Shipman, 2020, An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review, J Am Acad Dermatol., 82, 709, 10.1016/j.jaad.2019.07.027 Ototake, 2019, Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients, J Dermatol., 46, 285, 10.1111/1346-8138.14802 Pinard, 2019, Systemic treatment for clinically amyopathic dermatomyositis at 4 tertiary care centers, JAMA Dermatol., 155, 494, 10.1001/jamadermatol.2018.5215 Anyanwu, 2017, The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy, Int J Womens Dermatol., 3, 189, 10.1016/j.ijwd.2017.05.001 Chen, 2021, Myeloid dendritic cells are major producers of interferon-β in dermatomyositis and may contribute to hydroxychloroquine refractoriness, J Invest Dermatol., 141, 1906, 10.1016/j.jid.2020.12.032 Akabane, 2021, Adverse cutaneous reactions secondary to hydroxychloroquine in patients with dermatomyositis, lupus erythematosus, and lichen planopilaris, J Am Acad Dermatol., 10.1016/j.jaad.2021.02.034 Kumar, 2019, Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013, J Am Acad Dermatol., 80, 1658, 10.1016/j.jaad.2019.01.040 Lakhanpal, 1988, Eosinophilic fasciitis: Clinical spectrum and therapeutic response in 52 cases, Semin Arthritis Rheum., 17, 221, 10.1016/0049-0172(88)90008-X Jachiet, 2015, The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: Data from a French nationwide study of fifty-seven patients, Arthritis Rheumatol., 67, 527, 10.1002/art.38956 Kolkhir, 2019, Treatment of urticarial vasculitis: A systematic review, J Allergy Clin Immunol., 143, 458, 10.1016/j.jaci.2018.09.007 Hunt, 2021, Successful systemic treatment outcomes of lichen planus: A single-center retrospective review, Dermatol Ther., e14903 Ramírez, 2012, Childhood actinic lichen planus: Successful treatment with antimalarials, Australas J Dermatol., 53, e10, 10.1111/j.1440-0960.2010.00695.x Yeshurun, 2019, Hydroxychloroquine sulphate therapy of erosive oral lichen planus, Australas J Dermatol., 60, e109, 10.1111/ajd.12948 Eisen, 1993, Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: An open trial, J Am Acad Dermatol., 28, 609, 10.1016/0190-9622(93)70082-5 Rivas-Tolosa, 2016, Antimalarial drugs for the treatment of oral erosive lichen planus, Dermatology., 232, 86, 10.1159/000439588 Vermeer, 2021, The use of hydroxychloroquine as a systemic treatment in erosive lichen planus of the vulva and vagina, Br J Dermatol., 10.1111/bjd.19870 Nic Dhonncha, 2017, The role of hydroxychloroquine in the treatment of lichen planopilaris: A retrospective case series and review, Dermatol Ther., 30, 10.1111/dth.12463 Chiang, 2010, Hydroxychloroquine and lichen planopilaris: Efficacy and introduction of Lichen Planopilaris Activity Index scoring system, J Am Acad Dermatol., 62, 387, 10.1016/j.jaad.2009.08.054 Naeini, 2017, Clinical efficacy and safety of methotrexate versus hydroxychloroquine in preventing lichen planopilaris progress: A randomized clinical trial, Int J Prev Med., 8, 37, 10.4103/ijpvm.IJPVM_156_17 Ho, 2019, Medical therapy for frontal fibrosing alopecia: A review and clinical approach, J Am Acad Dermatol., 81, 568, 10.1016/j.jaad.2019.03.079 Samrao, 2010, Frontal fibrosing alopecia: A clinical review of 36 patients, Br J Dermatol., 163, 1296, 10.1111/j.1365-2133.2010.09965.x Vañó-Galván, 2014, Frontal fibrosing alopecia: A multicenter review of 355 patients, J Am Acad Dermatol., 70, 670, 10.1016/j.jaad.2013.12.003 Yun, 2018, Alopecia areata treated with hydroxychloroquine: A retrospective study of nine pediatric cases, Pediatr Dermatol., 35, 361, 10.1111/pde.13451 Boonpiyathad, 2017, Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous urticaria, randomized single-blinded placebo-controlled trial and an open label comparison study, Eur Ann Allergy Clin Immunol., 49, 220, 10.23822/EurAnnACI.1764-1489.11 Grewal, 2017, Antimalarial therapy for granuloma annulare: Results of a retrospective analysis, J Am Acad Dermatol., 76, 765, 10.1016/j.jaad.2016.11.044 Cannistraci, 2005, Treatment of generalized granuloma annulare with hydroxychloroquine, Dermatology., 211, 167, 10.1159/000086452 Durupt, 2008, Successful treatment of necrobiosis lipoidica with antimalarial agents, Arch Dermatol., 144, 118, 10.1001/archderm.144.1.118 Kavala, 2010, Significant improvement in ulcerative necrobiosis lipoidica with hydroxychloroquine, Int J Dermatol., 49, 467, 10.1111/j.1365-4632.2010.04149.x Jones, 1990, Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas, J Am Acad Dermatol., 23, 487, 10.1016/0190-9622(90)70246-E Modi, 2008, Micropapular cutaneous sarcoidosis: Case series successfully managed with hydroxychloroquine sulfate, Cutis., 81, 351 Powell, 2017, Ulcerative sarcoidosis: A prototypical presentation and review, Cutis., 100, 312 Singal, 2012, Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda, Clin Gastroenterol Hepatol., 10, 1402, 10.1016/j.cgh.2012.08.038 Marchesi, 1984, A comparative trial of desferrioxamine and hydroxychloroquine for treatment of porphyria cutanea tarda in alcoholic patients, Photodermatol., 1, 286 Pareek, 2008, Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: A randomized, double-blind, multicentric study, Indian J Dermatol Venereol Leprol., 74, 18, 10.4103/0378-6323.38401 Murphy, 1987, Hydroxychloroquine in polymorphic light eruption: A controlled trial with drug and visual sensitivity monitoring, Br J Dermatol., 116, 379, 10.1111/j.1365-2133.1987.tb05852.x Magaña-García, 1994, Antimalarials for children, J Am Acad Dermatol., 30, 510, 10.1016/S0190-9622(08)81962-7 Wang, 2021, Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: A multicenter, randomized, double-blind, double-dummy, pilot study, J Am Acad Dermatol., 84, 543, 10.1016/j.jaad.2020.05.050 Jarrett, 1996, Hydroxychloroquine and chronic erythema nodosum, Br J Dermatol., 134, 373, 10.1111/j.1365-2133.1996.tb07635.x Ortega-Peña, 2021, Familiar dermatologic drugs as therapies for COVID-19, Actas Dermosifiliogr., 112, 118, 10.1016/j.ad.2020.09.004 Stojkovic-Filipovic, 2020, Treatment of COVID 19-repurposing drugs commonly used in dermatology, Dermatol Ther., 33, e13829, 10.1111/dth.13829 Choudhuri, 2021, The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 — a systematic review and meta-analysis, Indian J Med Microbiol., 10.1016/j.ijmmb.2021.03.002 Mendel, 2021, Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: Experience of the Systemic Lupus International Collaborating Clinics, Ann Rheum Dis., 80, 1, 10.1136/annrheumdis-2020-218164 Shah, 2020, The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic, Dermatol Ther., 33, e13524, 10.1111/dth.13524 Abena, 2020, Chloroquine and hydroxychloroquine for the prevention or treatment of novel coronavirus disease (COVID-19) in Africa: Caution for inappropriate off-label use in healthcare settings, Am J Trop Med Hyg., 102, 1184, 10.4269/ajtmh.20-0290 Singh, 2021, Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19, Cochrane Database Syst Rev., 2, CD013587 Mitjà, 2021, A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19, N Engl J Med., 384, 417, 10.1056/NEJMoa2021801